Building upon this rationale, scholars tried to assess the diagnostic performance of PSMA-targeted PET imaging in different types of neoplasms, including SGMs and especially ACC, in various clinical settings, such as staging in newly diagnosed patients and restaging in patients undergoing relapse of their disease [14,15,16,17,18,19]. The gene discussed is FOLH1; the disease is adrenal cortex carcinoma.